Nuevolution Announces Collaboration in Drug Discovery with Boehringer Ingelheim
Partnership to use Nuevolution's Chemetics® Technology for Lead Discovery
Story content courtesy of Nuevolution
Nuevolution announced last week that it has entered into collaboration with Boehringer Ingelheim, using Nuevolution's proprietary Chemetics® drug discovery technology. Within the framework of the collaboration, hundreds of millions of diverse small molecules will be screened to discover and advance drug candidates against drug targets of interest to Boehringer Ingelheim. The Chemetics® platform uses innovative DNA labeling to allow fragment-based drug screening at an unprecedented scale forming both small molecules and synthetic biologics.
Under the terms of the agreement, Boehringer Ingelheim will provide Nuevolution with an upfront payment, research funding, and milestone payments as candidate molecules progress through preclinical and clinical development and onto the market. In addition, Nuevolution is eligible to receive royalties on the commercial sales of approved products.